ORCID as entered in ROS
https://orcid.org/0000-0003-2036-8817
Select Publications
Journal articles
, 1985, 'Single-Strand-Specific Degradation of DNA during Isolation of Rat Liver Nuclei†', Biochemistry, 24, pp. 5803 - 5809, http://dx.doi.org/10.1021/bi00342a018
, 1985, 'Dose-dependent persistence of alkylation-induced single stranded regions in rat liver DNA in vivo', Cancer Letters, 28, pp. 27 - 33, http://dx.doi.org/10.1016/0304-3835(85)90088-6
, 1985, 'Enhancement of nitrosamine-induced structural damage in rat liver DNA by cell division', Proceedings of the American Association for Cancer Research, VOL. 26
, 1985, 'ENHANCEMENT OF NITROSAMINE-INDUCED STRUCTURAL DAMAGE IN RAT-LIVER DNA BY CELL-DIVISION', PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 26, pp. 97 - 97, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AGD9400383&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1985, 'Oncogenes. A possible role for cancer genes in human malignant disease', Medical Journal of Australia, 142, pp. 402 - 409, http://dx.doi.org/10.5694/j.1326-5377.1985.tb133155.x
, 1985, 'Patterns of structural change in DNA during tissue necrosis indicated by benzoylated DEAE-cellulose chromatography', Chemico-Biological Interactions, 53, pp. 247 - 255, http://dx.doi.org/10.1016/S0009-2797(85)80102-2
, 1984, 'DIFFERENTIAL REPAIR OF ALKYLATION DAMAGE IN RAT-LIVER CHROMATIN', MEDICAL AND PEDIATRIC ONCOLOGY, 12, pp. 278 - 279, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984TC60000027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1984, 'FACTORS AFFECTING THE PERSISTENCE OF ALKYLATION-INDUCED STRUCTURAL DAMAGE IN DNA INVIVO', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 16, pp. S18 - S18, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984ANC4600033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1984, 'Limitations on the stability of benzoylated DEAE-cellulose', Analytical Biochemistry, 139, pp. 363 - 366, http://dx.doi.org/10.1016/0003-2697(84)90018-6
, 1983, 'REPLICATIVE INTERMEDIATES IN MAMMALIAN DNA', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 15, pp. 69 - 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RC51300166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1983, 'STRUCTURAL INTERMEDIATES GENERATED DURING REPLICATION OF MAMMALIAN DNA', MEDICAL AND PEDIATRIC ONCOLOGY, 11, pp. 198 - 199, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983QX04200045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1981, 'Sizing of DNA fragments by preparative, benzoylated DEAE-cellulose chromatography', FEBS Letters, 133, pp. 72 - 74, http://dx.doi.org/10.1016/0014-5793(81)80473-5
, 1981, 'ANALYSIS OF CHEMICALLY-INDUCED STRUCTURAL-CHANGE IN DNA BY BENZOYLATED-DEAE-CELLULOSE CHROMATOGRAPHY', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 14, pp. 90 - 90, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1981LR25400218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Papers
, 2022, 'Establishment and application of patient-derived xenograft models for personalised medicine in paediatric cancer', Sydney, presented at
, 2022, 'MULTI-PLATFORM TYROSINE KINASE PROFILING REVEALS NOVEL ACTIONABLE
FGFR ABERRATIONS ACROSS PEDIATRIC AND ADOLESCENT AND YOUNG ADULT
SARCOMAS', Vancouver, Canada, presented at
, 2021, 'Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR', in Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR, American Association for Cancer Research (AACR), pp. 639 - 639, presented at
, 2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at
, 2020, 'POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, pp. 289 - 290, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, pp. 292 - 292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric and
AYA sarcoma', Virtual, presented at
, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric
sarcoma patients', Virtual, presented at
, 2020, 'Precision medicine for high-risk paediatric and AYA sarcomas', Lorne, presented at
, 2019, 'Personalised medicine for high-risk paediatric and AYA sarcoma patients', Tokyo, Japan, presented at
, 2019, 'Precision medicine for high-risk paediatric and AYA sarcomas', Sydney, presented at
, 2019, 'Abstract 2616: A novel iron-chelating agent reduces MYC transcription via E2F gene family regulation', in Molecular and Cellular Biology / Genetics, American Association for Cancer Research, pp. 2616 - 2616, presented at
, 2019, 'Abstract 3659: Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in Tumor Biology, American Association for Cancer Research, pp. 3659 - 3659, presented at
, 2019, 'Abstract 3809: Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells', in Cancer Research, American Association for Cancer Research (AACR), pp. 3809 - 3809, http://dx.doi.org/10.1158/1538-7445.am2019-3809
, 2019, 'A novel iron-chelating agent reduces MYC transcription via E2F gene family regulation', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at
, 2019, 'Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at
, 2018, 'Chromatin destabilization by CBL0137 and panobinostat leads to complete tumour regression of childhood neuroblastoma in immunocompetent transgenic mice', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, Dublin, pp. E25 - E25, presented at
, 2018, 'Eradication of neuroblastoma by suppressing the expression of a single noncoding RNA', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at
, 2017, 'ABCE1 regulates the translational profile of neuroblastoma to drive tumor progression', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at
, 2017, 'Abstract 4056: A modulator of multidrug resistance protein 1 selectively depletes glutathione and synergizes with L-buthionine sulfoximine to sensitize MRP1-expressing cancer cells to chemotherapy', in Cancer Research, American Association for Cancer Research (AACR), DC, Washington, pp. 4056 - 4056, presented at
, 2017, 'AMX-513 polyamine depletion therapy inhibits tumor growth and reverses immunosuppression in cancers including MYC-driven neuroblastoma and pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at
, 2017, 'Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at
, 2017, 'Targeting tumor-amplified ODC1 with difluoromethylornithine (DFMO) inhibits global protein translation and has antitumor activity in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at
, 2016, 'Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, pp. S7 - S7, http://dx.doi.org/10.1016/S0959-8049(16)61016-X
, 2016, 'COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, ENGLAND, Liverpool, pp. 51 - 51, presented at
, 2016, 'Dextran-Catechin conjugate: An anticancer nano-modified natural compound targeting copper metabolism in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at
, 2016, 'MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at
, 2015, 'Molecular profiling of relapsed childhood cancer', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, UT, Salt Lake, presented at
, 2015, 'Examining the role of ABCA1 cholesterol transporter in ovarian cancer spheroids', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at
, 2015, 'High DKC1 expression supports neuroblastoma tumor cell proliferation and is strongly associated with poor patient outcomes', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at
, 2015, 'PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at
, 2015, 'MYCN and is a therapeutic target in neuroblastoma', in MOLECULAR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, La Jolla, presented at
, 2014, 'CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 135 - 135, presented at
, 2014, 'NOVEL STRATEGIES TO TARGET THE C5 SUBCLASS OF HIGH-GRADE SEROUS OVARIAN CANCER (HGSC) USING PATIENT-DERIVED XENOGRAFTS.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 1018 - 1019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966501301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'TARGETING MITOCHONDRIA AND CELL METABOLISM AS A NOVEL THERAPEUTIC APPROACH IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, SINGAPORE, Singapore, pp. 47 - 47, presented at
, 2013, 'TARGETING MITOCHONDRIA AND METABOLISM AS A NOVEL THERAPEUTIC APPROACH IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, FL, Fort Lauderdale, pp. 21 - 21, presented at
, 2013, 'Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-kappa B and activates p53, is highly effective in two independent mouse models of neuroblastoma.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at
Filter by type
https://orcid.org/0000-0003-2036-8817